What Scleroderma Treatment Can and Cannot Change: Setting Realistic Expectations

The first thing she noticed was that her wedding ring no longer turned. Then her fingers went white in the frozen-food aisle, and a rheumatologist said a word she had to spell out for her sister over the phone. Now, a few weeks into a new prescription, she is asking the question almost everyone with this diagnosis eventually asks: what, exactly, is this medicine supposed to do?

Setting scleroderma treatment expectations honestly is harder than it sounds, because the answer has two halves that sit uncomfortably together. Modern care can change a great deal: the frequency of painful vasospasm, the burn of reflux, the speed at which lungs lose capacity. It cannot yet reach the switch that started the process, and it cannot promise that thickened skin will ever feel the way it once did.

This explainer walks through both halves with the evidence in hand, so that the conversation with your care team starts from what is known rather than what is hoped.

How scleroderma actually works, in one plain picture

The name comes from Greek and means hard skin, which describes the most visible feature but misses the machinery underneath. Three processes run at once. Small blood vessels are injured and narrow, starving tissue of oxygen. The immune system misfires and produces autoantibodies, which are proteins that mistakenly target the body’s own cells. And fibroblasts, the cells that normally lay down a little collagen to repair wounds, keep producing it long after any wound has healed. The result is scar-like tissue, called fibrosis, in the skin and sometimes in internal organs.

Doctors divide the condition into two broad families. Localized scleroderma affects skin and the tissue just beneath it, often in patches (morphea) or bands (linear scleroderma), and rarely touches internal organs. Systemic sclerosis, the form most treatment discussions concern, can involve blood vessels, the digestive tract, lungs, heart and kidneys. Within systemic disease there are two patterns. Limited cutaneous disease keeps skin thickening below the elbows and knees, often with a long history of Raynaud’s phenomenon, the color change in fingers on cold exposure. Diffuse cutaneous disease spreads skin changes to the trunk and upper limbs and carries a higher early risk to internal organs (NIH NIAMS).

Why does this matter for expectations? Because treatment targets each process separately. Vasodilators open blood vessels. Immunosuppressants quiet the immune attack. Antifibrotic medicines slow the collagen factory. No single medicine acts on all three, and none acts on the original trigger, which remains unknown (NHS). Once you see the condition as three overlapping problems rather than one, the shape of a treatment plan, and its limits, becomes far easier to read.

What scleroderma treatment can realistically change

Start with the good news, because there is a fair amount of it. The most reliably changeable parts of scleroderma are the ones driven by blood vessel spasm and by acid. Raynaud’s attacks respond to a combination of warmth, stress management and, when needed, vasodilating medicines such as calcium channel blockers, which relax the muscle in artery walls (Mayo Clinic). Fewer attacks means fewer fingertip sores, and fewer sores means fewer infections and less lost work.

Reflux, which affects most people with systemic sclerosis because the lower esophagus weakens, is usually controllable with acid-suppressing medicines and meal timing. Joint stiffness, tendon friction and skin itch respond to physical therapy, moisturizers and, where appropriate, anti-inflammatory approaches chosen by the treating team.

Then there is the middle ground: things treatment can slow rather than stop. In diffuse disease with rapidly thickening skin, immunosuppressant medicines have been shown in clinical trials to reduce the rate of skin progression over months. In interstitial lung disease, which is scarring within the lung tissue, both immunosuppressants and an antifibrotic medicine have slowed the decline in lung capacity measured on breathing tests. Slowed, not restored. For pulmonary arterial hypertension, high pressure in the arteries feeding the lungs, several classes of vasodilator improve exercise capacity and symptoms (Mayo Clinic).

One change deserves its own sentence. Scleroderma renal crisis, a sudden dangerous rise in blood pressure with kidney injury, was once the leading cause of death in the condition. The introduction of ACE inhibitors, medicines that block a blood-pressure hormone pathway, transformed it into an emergency that can very often be managed if caught early (Johns Hopkins). That single shift is why blood pressure checks feature so heavily in modern follow-up.

What scleroderma treatment cannot change, at least not yet

Here is the harder half. No available medicine turns off the autoimmune process that drives scleroderma. Immunosuppressants dampen it; they do not reset it. Stopping such a medicine, a decision that belongs to the prescribing clinician, is generally followed by a return of activity rather than continued remission, which tells you the underlying signal is still there.

Fibrosis that has already formed is largely permanent. Lung scarring seen on a CT scan does not dissolve. Skin that has thickened and tethered to deeper tissue can loosen, but usually because the disease itself enters a quieter phase, not because a medicine reversed it. In diffuse disease, skin tends to thicken most in the early years and then gradually soften on its own; this natural history is one reason skin scores in clinical trials are notoriously difficult to interpret (Johns Hopkins).

Some features have no treatment with convincing evidence. Calcinosis, chalky calcium deposits under the skin, can be drained or surgically removed when they break through, but nothing reliably prevents new ones. Telangiectasias, the small red vessel marks on face and hands, are cosmetic and can be treated with laser, yet they return. Fatigue, which many people rank as their most disabling symptom, has no targeted therapy; pacing, sleep, activity and treating anemia or low thyroid where present are what the evidence supports (Cleveland Clinic).

Finally, treatment cannot tell you your future. Autoantibody patterns and disease subtype shift the odds of particular complications, but they are probabilities across groups, not a schedule for one person. Anyone who says otherwise is describing averages, and averages have never lived in a single body.

Can scleroderma be stopped from progressing?

People type this question into search engines more than almost any other about the condition, and the honest answer has layers. The disease as a whole cannot currently be halted. Progression in particular organs can, in many people, be slowed substantially, and in some it appears to stall for long stretches, though whether that reflects treatment or the natural rhythm of the illness is often impossible to separate.

The strongest evidence concerns the lungs. Randomized trials of immunosuppressants in scleroderma-related interstitial lung disease showed a smaller decline in forced vital capacity, the volume of air a person can forcibly exhale, compared with placebo over the study period. A separate antifibrotic medicine, first developed for a different lung scarring disease, reduced the annual rate of lung function loss in people with systemic sclerosis (Mayo Clinic). Neither improved lung function on average. Both bought time.

Autologous stem cell transplantation, in which a person’s own blood-forming cells are collected, the immune system is reset with intensive chemotherapy, and the cells are returned, has shown in trials that it can improve long-term outcomes for carefully selected people with severe, early diffuse disease. It carries real risk, including treatment-related death, which is why eligibility criteria are strict and the decision rests with a specialist transplant team after extensive testing (NIH NIAMS). It is not a routine option, and it is not a reset for everyone.

So the realistic framing is this: treatment aims to change the slope of the line, not to draw a flat one. For the lungs, kidneys and skin, that change in slope is meaningful and measurable. For the disease’s root cause, the line is still being drawn by biology.

How fast does scleroderma progress? Two very different clocks

Ask three people with systemic sclerosis how quickly things changed and you may hear three timelines. That variation is not noise; it reflects the two subtypes running on different clocks.

In diffuse cutaneous disease, skin thickening usually advances most rapidly in the first few years after onset, then reaches a plateau and often begins to soften. Internal organ complications, including lung scarring and renal crisis, cluster in this same early window, which is why specialists describe the first years of diffuse disease as the period of greatest vigilance (Johns Hopkins). Someone whose skin is still actively tightening is, in general, someone whose organs also need close watching.

Limited cutaneous disease moves on a much slower clock. Raynaud’s phenomenon can precede any skin change by years, sometimes many years. Skin involvement stays distal and often changes little over a decade. The complications that do occur, such as pulmonary arterial hypertension or severe gut involvement, tend to appear later in the course rather than early (NIH NIAMS). Slow does not mean harmless; it means the monitoring schedule looks different.

Localized scleroderma follows yet another pattern. Morphea patches often remain active for a few years and then fade, leaving color change or thinning rather than ongoing spread (NHS).

What no clock can tell you is where you personally fall. Autoantibody type helps: certain antibodies associate with rapid skin progression, others with lung or vascular complications. Yet these associations describe risk across populations. The practical translation is that your team will set the frequency of lung tests, heart scans and blood pressure checks according to your subtype and antibodies, and adjust as your own pattern reveals itself.

Who is usually treated intensively, and who is asked to watch and wait

Not everyone with scleroderma is handed an immunosuppressant, and that surprises people who arrive expecting the strongest medicine available. Treatment intensity is matched to what is active and what is at stake.

Intensive, organ-directed therapy is generally considered for people with early diffuse disease and rapidly progressing skin, for anyone with interstitial lung disease that is worsening on breathing tests or CT scans, for pulmonary arterial hypertension confirmed by specialist testing, and for renal crisis, which is treated as an emergency (Mayo Clinic). The logic is simple: these are the situations where evidence shows treatment changes trajectory, and where delay costs function that cannot be recovered.

People with limited disease, stable skin, normal lung function and a normal echocardiogram are usually offered symptom-directed care and structured monitoring instead. This is sometimes called watchful waiting, a phrase that undersells it. Watching, in scleroderma, means annual breathing tests, heart ultrasound, regular blood pressure and urine checks, and a low threshold for repeating imaging if symptoms shift (Johns Hopkins). It is active surveillance with a plan attached, not neglect.

Why not treat everyone aggressively just in case? Because immunosuppressants raise infection risk, can affect blood counts and liver function, and require their own monitoring. Exposing someone whose disease is quiet to those risks, without evidence of benefit in their situation, is not caution; it is a different kind of harm. Guideline-level practice therefore reserves the heavier tools for measurable activity.

Where you sit on this spectrum can change. A stable person can develop new lung findings; an active person can settle. The category is a snapshot, revisited at every visit, and the decision about moving between categories sits with the treating rheumatologist.

Limited versus diffuse: what to expect, side by side

Because so many expectations hinge on subtype, it helps to see the two patterns next to each other. The table summarizes typical features described by major medical sources; individual courses vary, and your team’s assessment overrides any general pattern.

Feature	Limited cutaneous systemic sclerosis	Diffuse cutaneous systemic sclerosis
Skin involvement	Fingers, hands, forearms, feet, face	Extends to upper arms, thighs, trunk
Raynaud’s timing	Often years before other signs	Usually close to onset of skin change
Speed of skin change	Slow, often stable for years	Rapid in early years, then tends to plateau
Period of highest organ risk	Later in the course	First few years
Complications to monitor closely	Pulmonary arterial hypertension, gut, digital ulcers	Interstitial lung disease, renal crisis, heart
Typical treatment emphasis	Symptom control, vascular therapy, surveillance	Immunosuppression when active, plus surveillance

Sources: NIH NIAMS; Johns Hopkins.

Two cautions when reading it. First, limited does not mean mild. Pulmonary arterial hypertension and severe esophageal disease can be life-altering, and they occur in limited disease. Second, the diffuse column’s early intensity is also its opportunity: this is the window in which treatment evidence is strongest, which is why early referral and prompt baseline testing matter more here than almost anywhere else in rheumatology (Mayo Clinic).

Raynaud's and finger ulcers: the part of treatment you feel first

For many people the hands are where scleroderma is lived day to day, and they are also where treatment expectations are most often either too high or too low. Nearly everyone with systemic sclerosis has Raynaud’s phenomenon (NIH NIAMS). In scleroderma, unlike the common primary form, the small arteries are structurally narrowed, not just twitchy, so the attacks are more severe and can end in fingertip sores, called digital ulcers, that heal slowly because blood supply is poor.

Treatment can reliably reduce attack frequency and severity. Keeping the whole body warm, not just the hands, matters because the body diverts blood from the extremities when the core cools. Avoiding smoking and nicotine, which constrict vessels further, is one of the few lifestyle measures with a clear mechanism and consistent guidance behind it (NHS). Medicines that relax artery walls, including calcium channel blockers and, in more severe cases, phosphodiesterase inhibitors or intravenous prostacyclin analogues, are chosen and adjusted by the treating team based on how often attacks and ulcers recur.

What treatment cannot do is restore the arteries to normal caliber. The narrowing is fixed, so cold will always be a threat, and a person with severe vascular disease may still develop an ulcer despite doing everything right. That is not failure; it is the ceiling of current therapy.

Healing an ulcer once it forms is a slower business than most people expect. Protecting it, keeping it clean, controlling pain and watching for infection are the priorities. Some medicine classes have been shown to reduce the number of new ulcers, which is a prevention effect rather than a healing one. If a fingertip turns dusky or black, or an ulcer becomes hot and produces pus, that is a same-day call, not a wait-for-the-appointment issue.

Skin, joints and mouth: will the tightness ever ease?

Skin is the symptom people can see in the mirror, so it is natural to judge treatment by it. The evidence suggests that is a mistake, or at least a misleading yardstick.

In diffuse disease, skin thickness measured by pinching at standard sites tends to rise for a few years and then fall, with or without immunosuppression. Treatment appears to blunt the peak and possibly hasten the decline, but softening that arrives in year three or four may be the disease settling rather than the medicine working (Johns Hopkins). Clinicians therefore watch skin as one signal among several, not as the verdict.

What can be changed is function. Fingers curled by tight skin and shortened tendons respond to daily stretching, paraffin wax warmth and hand therapy far better than most people assume, provided the routine starts before contractures become fixed (Cleveland Clinic). Itch, which is intense in the active phase, eases with emollients and often fades as the disease quiets. Joint pain and the creaking sensation over tendons, called tendon friction rubs, tend to accompany active diffuse disease and lessen as it does.

The mouth has its own agenda. Facial skin tightening reduces how wide the mouth opens, which complicates dental care and eating. Stretching exercises help preserve opening; nothing restores lost elasticity. Dry mouth, common because the same process affects saliva glands, raises cavity risk, so dental visits move from optional to essential.

Expect, then, a two-track story. The appearance and texture of skin follow the disease’s own timetable, which treatment nudges. The usefulness of your hands and mouth follows the effort you and your therapists put in, and that track is genuinely in reach.

Lungs, heart and kidneys: why monitoring is half the treatment

If you leave a scleroderma appointment with a list of tests rather than a new prescription, you have not been fobbed off. In this condition, detection is treatment’s front door, because the complications that shorten life are quiet until they are not.

Interstitial lung disease can exist for years with only mild breathlessness on stairs. Breathing tests measuring lung volume and gas transfer, alongside high-resolution CT scanning when indicated, catch decline before it is felt. Specialist centers commonly repeat lung function testing at least yearly, and more often in early diffuse disease or when a trend appears (Johns Hopkins). A falling number is the trigger for treatment decisions, which is why the number needs to exist.

Pulmonary arterial hypertension is screened with an echocardiogram, an ultrasound of the heart, and confirmed by measuring pressures directly through a catheter. It develops most often in longstanding limited disease and responds to several vasodilator classes that improve symptoms and exercise capacity when started before the right side of the heart is exhausted (Mayo Clinic).

Renal crisis announces itself with a sharp rise in blood pressure, sometimes with headache, visual change or sudden fatigue, in a person who may have had normal readings weeks earlier. Home blood pressure monitoring in early diffuse disease is widely recommended for exactly this reason, and a reading well above a person’s usual is an urgent call. Certain medicines, including higher-dose corticosteroids, are associated with increased renal crisis risk, which shapes how sparingly they are used; any such decision belongs to the prescribing clinician (NIH NIAMS).

Heart muscle involvement and rhythm problems are less common and harder to screen, which is one more reason unexplained palpitations, fainting or new swelling should reach your team promptly.

What the first months after diagnosis usually look like

The weeks after a scleroderma diagnosis rarely feel like a treatment plan; they feel like a schedule. That is by design.

Early on, expect baseline testing: blood work including autoantibody typing, lung function tests, a chest CT if breathing tests or symptoms warrant, an echocardiogram, urine analysis and blood pressure. These establish the starting line against which every later result is compared (Mayo Clinic). Without them, a slightly low lung volume a year from now is uninterpretable; with them, it is a trend.

If organ-directed treatment is started, the timeline of expectations is slow. Immunosuppressants and antifibrotics do not produce a felt change in days. Trials assessing their effect on skin and lung function measured outcomes over many months, and clinicians generally judge response over a similar span rather than at the next visit (Mayo Clinic). Side effects, by contrast, can appear early, which is why blood tests are scheduled more frequently at the start. Vasodilators for Raynaud’s are the exception; their effect on attack frequency is usually noticeable within weeks.

Referrals typically multiply in this period: hand therapy, a dietitian if swallowing or reflux is troublesome, a dentist, sometimes pulmonology or cardiology. Each is a piece of the multidisciplinary approach that guideline-level care describes, and each addresses a part of the condition the rheumatologist’s prescription does not reach.

Emotionally, the first months are often the hardest, not because the disease is at its worst but because uncertainty is. Many people describe a turning point around the first set of repeat tests, when trend lines begin to replace guesswork. Until then, the most useful expectation is patience with a plan that is deliberately built on measurement.

What triggers a scleroderma flare-up? Separating triggers from progression

Scleroderma flare up triggers are searched constantly, and the search often rests on a misunderstanding worth correcting gently. Unlike lupus or rheumatoid arthritis, systemic sclerosis does not typically flare and remit in dramatic cycles. It moves, in most people, as a slow tide. What people experience as flares are usually one of three things: a Raynaud’s cluster, a symptom surge from a specific organ, or genuine disease progression that happens to become noticeable all at once.

Raynaud’s has clear, evidence-based triggers. Cold is the obvious one, and it includes air conditioning, refrigerated aisles and holding a cold drink. Emotional stress provokes the same vessel constriction through adrenaline. Smoking and nicotine products narrow arteries further. Some over-the-counter decongestants and certain migraine or attention-deficit medicines constrict vessels too, which is why your team asks about everything you take (NHS). Vibration from tools can worsen attacks in the hands.

Gut symptoms have their own set. Large late meals, lying down soon after eating, alcohol and caffeine worsen reflux when the esophageal valve is weak. Bloating and alternating bowel habits can follow antibiotic courses or dietary shifts because gut motility is slowed.

Infections deserve mention. Any illness that raises inflammation can make fatigue, joint pain and breathlessness feel abruptly worse for a period, particularly in someone taking immunosuppressants. That is usually the infection, not the scleroderma, and it usually settles.

True progression, such as a step-down in lung function or new skin spread, is not known to be triggered by identifiable events in the way Raynaud’s is. The evidence does not support the idea that a stressful month or a poor diet causes fibrosis to advance, and guilt on that point is misplaced (Cleveland Clinic). What you can control are the triggers of symptoms; what you monitor for is the tide.

What people often get wrong about scleroderma treatment

Some misconceptions are harmless. Others quietly steer decisions, so they are worth naming.

Myth: if the medicine were working, my skin would be soft by now. Skin follows a multi-year arc in diffuse disease, and the medicines with the best evidence were tested mainly against lung function and skin scores over long periods. Judging a plan by texture at three months mismatches the tool to the timeline (Johns Hopkins).

Myth: limited scleroderma means I do not need lung or heart tests. Pulmonary arterial hypertension occurs disproportionately in longstanding limited disease. Surveillance is lighter in frequency, not absent (NIH NIAMS).

Myth: a strict diet or supplement can stop the fibrosis. No dietary pattern or supplement has been shown in controlled trials to slow skin or lung scarring in systemic sclerosis. Nutrition matters enormously for weight, reflux and bowel symptoms, which is reason enough to see a dietitian, but it is not disease-modifying therapy. Presenting it as such is not supported by evidence (Cleveland Clinic).

Myth: stem cell transplant is the new standard and I should push for it. It has strong evidence in a narrow group with severe early diffuse disease, and it carries serious risks. Eligibility depends on organ function, age and disease stage, and the assessment belongs to a specialist team.

Myth: feeling well means the disease is inactive. Lung scarring and rising pulmonary pressures can be symptom-free for a long time. This is the single most important reason to keep appointments when you feel fine.

Myth: a diagnosis of scleroderma is uniformly grave. Outcomes span an enormous range. Many people with limited disease live for decades with manageable symptoms, and early recognition of organ involvement has shifted the picture substantially (NHS). Realistic is not the same as bleak.

Questions to ask your care team about scleroderma treatment expectations

Appointments are short and the condition is not. A prepared list turns a rushed review into a conversation about your specific trajectory. These questions are designed to surface expectations rather than assume them.

• Which subtype do I have, and which autoantibodies were found? What do those patterns usually mean for the organs you will watch most closely in my case?
• What is each medicine I take actually aiming to do: relieve a symptom, slow an organ process, or prevent an emergency? How will we know whether it is doing that, and over what timeframe?
• What monitoring schedule are we following for lungs, heart, kidneys and blood pressure, and what result would change the plan?
• Should I be checking blood pressure at home, and what reading should prompt a same-day call?
• What side effects of my treatment need urgent attention, and which can wait for the next visit?
• Are there medicines, including over-the-counter or prescribed by other doctors, that I should avoid or flag because of my scleroderma?
• Which allied professionals, such as hand therapy, dietetics, dental care, respiratory or cardiology, should be part of my team now rather than later?
• If my disease stays stable, what would a lighter plan look like? If it progresses, what are the next options, and would I be a candidate for any of them?
• Is there a clinical trial that fits my situation, and how would I learn about one?
• Who do I contact between appointments, and how quickly should I expect a response?

Write the answers down, or ask permission to record them. Expectations that live only in memory drift toward hope or fear over a long illness. The ones written in your own hand, next to the numbers from your tests, tend to stay honest (MedlinePlus).

When to call your doctor

Most of scleroderma is managed at scheduled visits, and most changes can wait for the next one. A short list cannot. These are the situations where the evidence on complications says minutes and hours matter, and where the right move is to contact your team the same day or seek emergency care rather than to watch and see (Mayo Clinic; NIH NIAMS).

• A blood pressure reading well above your usual, especially with a new severe headache, blurred vision, confusion or sudden marked fatigue: possible renal crisis, which is a medical emergency.
• Breathlessness that has worsened noticeably over days or a couple of weeks, or breathlessness at rest, or new chest pain or pressure.
• Fainting, near-fainting, or a fast or irregular heartbeat that is new for you.
• A fingertip or toe that turns dusky, blue or black and does not recover with warmth, or an ulcer that becomes hot, swollen, foul-smelling or leaks pus, or is accompanied by fever.
• Vomiting blood or passing black stools, or severe abdominal pain with bloating and inability to pass stool or gas.
• Fever or signs of infection while taking an immunosuppressant, since these medicines can mask and worsen infections.
• New leg swelling on one side, or sudden calf pain.
• Passing much less urine than usual over a day, or urine that is dark or blood-tinged.

None of these signs confirms a complication on its own; each is a reason for assessment rather than a diagnosis. If you are ever unsure whether something qualifies, the safer expectation is that your team would rather hear from you than not. Every decision about treatment changes, tests or hospital care that follows such a call belongs to the clinicians who know your history, and calling early gives them the most room to act.

Frequently asked questions

Can you stop scleroderma from progressing?

Not entirely, with current treatments. The underlying autoimmune process cannot be switched off, but progression in specific organs can often be slowed. Trials show immunosuppressants and an antifibrotic medicine reduce the rate of lung function decline, and immunosuppression can blunt rapid skin thickening in diffuse disease. Your rheumatologist decides whether and when such treatment fits your situation based on measured activity.

How fast does scleroderma progress?

It depends heavily on subtype. Diffuse cutaneous disease usually changes fastest in the first few years, with skin thickening and organ complications clustering early before a plateau. Limited cutaneous disease moves slowly, often over decades, with Raynaud’s preceding other signs by years and complications such as pulmonary hypertension appearing later. Individual courses vary widely, which is why monitoring schedules are personalized.

What triggers a scleroderma flare-up?

Systemic sclerosis does not usually flare in cycles like lupus. What feels like a flare is often a Raynaud’s cluster triggered by cold, stress, nicotine or vessel-constricting medicines such as decongestants, or a reflux surge from late meals, alcohol or lying down after eating. Infections can temporarily worsen fatigue and breathlessness. Actual progression of fibrosis is not known to be triggered by identifiable events.

What is the life expectancy with systemic scleroderma?

It spans a very wide range and depends mainly on subtype and which organs are involved. Many people, particularly those with limited cutaneous disease and no serious lung, heart or kidney complications, live for decades with manageable symptoms. Lung disease and pulmonary hypertension are the main factors that shorten life today. Your own team can interpret your antibody pattern and test trends far better than any general figure.

Can you live 20 years with systemic scleroderma?

Yes, many people do, and some live considerably longer. Longer survival is more typical in limited disease and in people whose lung and heart tests stay stable over time. Early detection of organ involvement through regular monitoring, and the availability of effective treatment for renal crisis, have shifted outcomes over recent decades. No one can promise an individual timeline, but two decades is not unusual.

Does scleroderma skin ever soften?

Often, yes, especially in diffuse disease. Skin thickness typically increases during the first few years and then gradually softens as the disease enters a quieter phase, with or without treatment. Immunosuppression may lower the peak and speed the decline, but softening is not a reliable sign that a medicine is working. Hand and mouth stretching preserves function while the skin follows its own course.

Why do I need lung and heart tests when I feel fine?

Because the complications that matter most are silent early. Interstitial lung disease and pulmonary arterial hypertension can develop for years with little or no breathlessness. Breathing tests, CT scans when indicated, and echocardiograms detect decline before symptoms, and a measured change is what triggers treatment decisions. Feeling well is reassuring, but it is not the same as being stable on tests.

Is stem cell transplant a standard scleroderma treatment?

No. Autologous stem cell transplantation has shown benefit in trials for a carefully selected group with severe, early diffuse disease, but it carries significant risks including treatment-related death. Eligibility depends on organ function, disease stage and other factors assessed by a specialist transplant team. For most people with scleroderma, it is not an appropriate option, and the decision is never made on request alone.

Can diet or supplements slow scleroderma?

There is no controlled trial evidence that any diet or supplement slows skin or lung fibrosis in systemic sclerosis. Nutrition does matter for managing reflux, bowel symptoms, weight and dental health, and a dietitian is a valuable team member. Claims that a food plan can halt the disease are not supported by evidence, and any supplement should be discussed with your team because of possible interactions.

What does a high blood pressure reading mean in scleroderma?

It can be the first sign of scleroderma renal crisis, a sudden rise in blood pressure with kidney injury that is treated as a medical emergency. The risk is highest in early diffuse disease. A reading well above your usual, particularly with headache, visual change or sudden fatigue, warrants a same-day call to your team or emergency care. Home monitoring is commonly recommended for exactly this reason.

References

• Scleroderma (NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases)
• Scleroderma (NHS)
• Scleroderma: An Overview (Cleveland Clinic)
• Raynaud's (NHS)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.